



Drug Quantity Management – Per Days Prevymis™ (letermovir tablets) Duration Limit

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	2
Background.....	2
References	2
Revision History	2

Product Identifier(s)

66209

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Prevymis 240 mg, 480 mg tablets

Maximum quantity per 365 days = 100 tablets
(allow 28 tablets per dispensing)

The objective of this program is to manage potential treatment duration beyond 100 days of Prevymis in the prophylaxis of CMV infection and disease in adult recipients of an allogeneic HSCT. Extended treatment duration beyond 100 days can be obtained through coverage review.

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

1. For prophylaxis in high risk HSCT individuals with delayed immune reconstitution as a result of T-cell-depleted grafts and those being treated for GVHD, approve the treatment duration requested allowing 28 tablets per dispensing

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Prevymis is an antiviral drug that is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). The recommended dosage of Prevymis is 480 mg administered orally once daily. Initiate Prevymis between Day 0 and Day 28 post-transplantation (before or after engraftment), and continue through Day 100 post-transplantation. Dosage of Prevymis should be adjusted when co-administered with cyclosporine. If Prevymis is co-administered with cyclosporine, the dosage of Prevymis should be decreased to 240 mg once daily.

References

1. Prevymis™ [prescribing information]. Whitehouse Station, NJ: Merck Sharpe & Dohme Corp.; December 2019.
2. Marty FM, Ljungman RF, Cemaly J, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med 2017; 377:2433-44.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	Reviewed by Clinical Specialists. No changes to criteria.	03/17/2020

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna